Wortmann G W, Aronson N E, Byrd J C, Grever M R, Oster C N
Infectious Disease Service, Walter Reed Army Medical Center, Washington, D.C. 20307-5001, USA.
Clin Infect Dis. 1998 Sep;27(3):509-12. doi: 10.1086/514689.
A review of 84 patients with cutaneous leishmaniasis treated with sodium stibogluconate (Pentostam) at our institution revealed that three had developed herpes zoster during or shortly after receiving therapy. Because zoster has been associated with depressed cellular immunity, we prospectively followed serial lymphocyte subpopulations in eight patients with cutaneous leishmaniasis who received Pentostam. By day 7 of therapy, the white blood cell count had fallen by a median of 1.15/mm3, the total lymphocyte count by a median of 804/mm3, and the CD4+ lymphocyte count by a median of 306/mm3 (67% of baseline; confidence interval, 52%-78%). An in vitro cell-viability assay demonstrated that Pentostam is not toxic to human mononuclear cells. The administration of Pentostam for the treatment of cutaneous leishmaniasis results in lymphopenia that may be related to the subsequent occurrence of herpes zoster.
对我院84例接受葡萄糖酸锑钠（喷他脒）治疗的皮肤利什曼病患者进行的一项回顾显示，有3例在接受治疗期间或治疗后不久发生了带状疱疹。由于带状疱疹与细胞免疫功能低下有关，我们对8例接受喷他脒治疗的皮肤利什曼病患者的系列淋巴细胞亚群进行了前瞻性随访。到治疗第7天时，白细胞计数中位数下降了1.15/mm³，总淋巴细胞计数中位数下降了804/mm³，CD4⁺淋巴细胞计数中位数下降了306/mm³（为基线的67%；置信区间为52%-78%）。一项体外细胞活力测定表明，喷他脒对人单核细胞无毒。使用喷他脒治疗皮肤利什曼病会导致淋巴细胞减少，这可能与随后发生带状疱疹有关。
